Table 2.
ICER for 5 Common Regimens Using Average 340b Pricing (base case scenario) and Average Wholesale Price (sensitivity analysis)
| Regimen | Median(mos) | Average 340b Pricea | ICER (340b Price/mos) |
|---|---|---|---|
| Emtricitabine, Tenofovir, Efavirenz | 40.1 | $710.64 | Reference |
| Emtricitabine, Tenofovir, Rilpivirine | 36.3 | $957.72 | Dominated |
| Emtricitabine, Tenofovir, ritonavir/ Atazanavir | 31.9 | $1060.35 | Dominated |
| Emtricitabine, Tenofovir, Raltegravir | 47.8 | $1075.03 | $47.32 |
| Emtricitabine, Tenofovir, ritonavir/Darunavir | 47.8 | $1166.07 | Dominated |
| Regimen | Median(mos) | Market Price | ICER (Market Price/mos) |
| Emtricitabine, Tenofovir, Rilpivirine | 36.3 | $2633.34 | Reference |
| Emtricitabine, Tenofovir, Efavirenz | 40.1 | $2658.24 | $6.55 |
| Emtricitabine, Tenofovir, Raltegravir | 47.8 | $3091.49 | $56.27 |
| Emtricitabine, Tenofovir, ritonavir/Darunavir | 47.8 | $3464.54 | Dominated |
| Emtricitabine, Tenofovir, ritonavir/ Atazanavir | 31.9 | $3475.47 | Dominated |
a
Average 340b Price is the average of four national wholesale pharmacies who provide discounted drugs via the 340b Prime Vendor Program
Definitions: ICER, Incremental Cost-Effectiveness Ratio, is calculated by comparing the difference in the cost divided by the difference in effect Dominated means that a treatment is less durable and more costly than the regimen in the preceding row